FMP
CTI BioPharma Corp.
CTIC
NASDAQ
Inactive Equity
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
9.1 USD
0.005 (0.05498%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Adam R. Craig M.B.A., M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.ctibiopharma.comexchange
NASDAQ
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
CIK
0000891293
ISIN
US12648L6011
CUSIP
12648L601
Address
3101 Western Avenue
Phone
206 282 7100
Country
US
Employee
127
IPO Date
Mar 21, 1997
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
CTIC Financial Summary
CIK
0000891293
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
12648L601
ISIN
US12648L6011
Country
US
Price
9.1
Beta
0.83
Volume Avg.
5.66M
Market Cap
1.2B
Shares
-
52-Week
4.01-9.1
DCF
6.52
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-16.84
P/B
-
Website
https://www.ctibiopharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CTIC News
It looks like there's no news available.
